SANA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
65.4M
+34.6%
48.6M
-20.6%
61.2M
+40.6%
43.5M
-54.2%
95.0M
R&D
54.6M
+47.1%
37.2M
+89.7%
19.6M
-41.1%
33.2M
-17.0%
40.0M
SG&A
10.8M
-6.0%
11.5M
-5.9%
12.2M
+18.5%
10.3M
-0.5%
10.3M
Operating Income
-65420000
-34.6%
-48614000
+20.6%
-61199000
-40.6%
-43515000
+54.2%
-94975000
EBITDA
-63186000
-36.7%
-46223000
+20.5%
-58146000
-44.2%
-40324000
+15.1%
-47507000
Net Income
-63635000
-34.8%
-47210000
+19.7%
-58825000
-39.6%
-42152000
+55.1%
-93800000
EPS (Basic)
$-0.22
-29.4%
$-0.17
+19.0%
$-0.21
-31.2%
$-0.16
+59.0%
$-0.39
EPS (Diluted)
$-0.22
-29.4%
$-0.17
+19.0%
$-0.21
-31.2%
$-0.16
+59.0%
$-0.39
Shares (Diluted)
295.7M
+6.8%
276.9M
+0.1%
276.5M
+6.1%
260.5M
+9.3%
238.4M
Sana Biotechnology (SANA) โ€” Financials